-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Unlike triple-negative or human epidermal growth factor receptor 2-positive breast cancers, in hormonal (i.
Clinicopathological factors known to be associated with the prognosis of Luminal breast cancer treated with NAC include: adherence to adjuvant endocrine therapy, clinical staging before NAC (hereinafter referred to as pre-NAC), pathological staging after NAC, nuclear grade, age, lymphatic vasion, polygene expression characteristics, and Ki-67 index
So far, the role of imaging in predicting pCR has been extensively studied, but little
Recently, a study published in the European Journal of Radiology explored the relationship between imaging (MRI, US and molybdenics) and clinicopathological variables in predicting the survival without distant metastasis (DMFS) and total survival (OS) in patients with Luminal breast cancer treated with NAC, providing theoretical support
This retrospective study collected patients with
The development cohort included 318 women (68 distant metastases, 54 deaths) and the validation cohort included 165 women (37 distant metastases, 14 deaths) (the median age of both cohorts was 46 years).
In this study, predictive models that combined imaging and clinicopathological variables showed good resolution
Original source:
Bo Ra Kwon,Sung Ui Shin,Soo-Yeon Kim,et al.